Joaquin Duato

Joaquin Duato, Chairman and CEO of Johnson & Johnson, joins to discuss the company's ambitious $55 billion U.S. investment commitment. He highlights innovations in medical devices and the integration of AI in accelerating cancer therapies. Duato also addresses the regulatory landscape, expressing confidence in U.S. innovation and talent. Insightful updates on talc litigation and J&J's financial health are shared, alongside their promising pipeline of products, showcasing the company’s strategic focus on long-term growth.

Joaquin Duato, the CEO of Johnson & Johnson, shares insights on the company’s strong earnings and a strategic split of its orthopedics business. He discusses the impact of FDA warnings on their treatment Carvykti and highlights exciting new products in the pipeline. Meanwhile, Andrew Ross Sorkin, a prominent financial journalist, promotes his new book, 1929, which delves into the dramatic stock market crash and its lasting effects on capitalism. He shares behind-the-scenes stories and the challenges of researching this tumultuous period.

Joaquin Duato, Chairman and CEO of Johnson & Johnson, discusses the power of saying 'Yes' to new opportunities, the importance of trust in managers, and the value of personal experiences in shaping career success. They also explore internal mobility, imposter syndrome, leadership responsibilities, and the significance of a strong mission in healthcare.